How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Omega-3 Ingredient for Pharmaceutical Market
- By Source Type: Fish Oil, Krill Oil, Algal Oil, Calcium Omega-3, Flaxseed Oil
- By Formulation Type: Ethyl Ester, Triglyceride, Phospholipid, Free Fatty Acid
- By Application: Cardiovascular Health, Cognitive Health, Inflammation Management, Eye Health, Pregnancy and Infant Nutrition
- By Dosage Form: Capsules, Softgels, Liquid Suspensions, Injectables, Tablets
- By Purity Grade: Pharmaceutical Grade, Food Grade, Nutraceutical Grade
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Fish Oil leads By Source Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Omega-3 Ingredient for Pharmaceutical Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Source Type 5
Formulation Type 4
Application 5
Dosage Form 5
Purity Grade 3
Companies profiled
DSM Nutritional Products
Croda International Plc
BASF SE
Martek Biosciences Corporation (a subsidiary of DSM)
Omega Protein Corporation
GC Rieber Oils AS
EPAX AS
Lysoveta
AlaskOmega
Ocean Nutrition Canada Ltd. (a subsidiary of DSM)
Cargill
Incorporated
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →DSM Nutritional Products
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Croda International Plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Martek Biosciences Corporation (a subsidiary of DSM)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Omega Protein Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GC Rieber Oils AS
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →EPAX AS
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Lysoveta
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AlaskOmega
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ocean Nutrition Canada Ltd. (a subsidiary of DSM)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cargill
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →OmegaQuant Analytics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Nissui Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Mitsubishi Corporation Life Sciences Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →K.D. Pharma Group GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,824M by 2033 · 5.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Fish Oil52.7
- Krill Oil8.6
- Algal Oil13.9
- Calcium Omega-316.2
- Flaxseed Oil8.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,637M → $2,463M · 5.2%
Europe$1,141M → $1,856M · 6.3%
Asia Pacific$1,042M → $1,804M · 7.1%
Latin America$644.8M → $959.6M · 5.1%
Middle East and Africa$496.0M → $715.0M · 4.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.812026
5.822027
5.842028
5.852029
5.872030
5.882031
5.882032
5.912033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- DSM Nutritional Products21.8
- Croda International Plc12.4
- BASF SE13.3
- Martek Biosciences Corporation (a subsidiary of DSM)8.8
- Omega Protein Corporation7.0
- GC Rieber Oils AS8.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Source Type21.5%
Formulation Type24.2%
Application14.0%
Dosage Form23.0%
Purity Grade17.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe23.8
- Asia Pacific23.1
- Latin America12.3
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| DSM Nutritional Products | 78 | 81 | 88 | 90 | 98 | 98 | 89 |
| Croda International Plc | 82 | 71 | 88 | 93 | 92 | 82 | 85 |
| BASF SE | 78 | 71 | 73 | 78 | 78 | 84 | 77 |
| Martek Biosciences Corporation (a subsidiary of DSM) | 79 | 57 | 66 | 76 | 71 | 69 | 70 |
| Omega Protein Corporation | 60 | 59 | 70 | 76 | 61 | 62 | 65 |
| GC Rieber Oils AS | 63 | 59 | 58 | 65 | 59 | 62 | 61 |
| EPAX AS | 46 | 57 | 63 | 46 | 58 | 45 | 53 |
| Lysoveta | 51 | 42 | 42 | 37 | 44 | 59 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- DSM Nutritional Products
- Croda International Plc
- BASF SE
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| DSM Nutritional Products | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Croda International Plc | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| BASF SE | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Martek Biosciences Corporation (a subsidiary of DSM) | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Omega Protein Corporation | ◐ | ◐ | ◐ | ✓ | − | − |
| GC Rieber Oils AS | ◐ | − | ◐ | ✓ | − | − |
| EPAX AS | ◐ | ◐ | ◐ | ◐ | − | − |
| Lysoveta | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1DSM Nutritional Products89
2Croda International Plc85
3BASF SE77
4Martek Biosciences Corporation (a subsidiary of DSM)70
5Omega Protein Corporation65
6GC Rieber Oils AS61
7EPAX AS53
8Lysoveta46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
DSM Nutritional ProductsCroda International Plc
Challenger2
Strong scale, closing on the leaders.
BASF SEMartek Biosciences Corporation (a subsidiary of DSM)
Contender2
Focused players with pockets of strength.
Omega Protein CorporationGC Rieber Oils AS
Niche2
Specialists in a single segment or region.
EPAX ASLysoveta
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Source Type in North America, then scale across Omega-3 Ingredient for Pharmaceutical Market — a $51M beachhead inside a $953M market.
Beachhead (SOM)$51Mobtainable near-term
Serviceable (SAM)$346Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Fish Oil
Best fit — highest urgency & budget in Source Type.
Economic buyer78 fit
Krill Oil
Strong fit — clear ROI and a fast path to value.
End user69 fit
Algal Oil
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Source Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Source Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Omega-3 Ingredient for Pharmaceutical Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified20%
Evaluation14%
Closed-won6%
$11.9KCAC
$45KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Omega-3 Ingredient for Pharmaceutical Market is a durable-growth opportunity — $5.86B by 2033, compounding at 6.2%.
TAM · 2025$3.61Btoday
TAM · 2033$5.86Bforecast
CAGR6.2%2027–2033
Cumulative$41.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.86BTotal addressable market
SAM$2.41BServiceable available market
SOM$430MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.2% CAGR
Demand compounds through 2033, outpacing GDP across Source Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Source Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.86BLarge & growingTAM by 2033 at 6.2% CAGR
$2.41BServiceable nowreachable with today’s model
$430MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.57BBear4.0% CAGR
$5.86BBase6.2% CAGR
$7.49BBull8.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Omega-3 Ingredient for Pharmaceutical Market — a $9.07B market by 2033. Plan: grow share from 9.1% to 16.5%.
Market size · 2033$9.07Btotal addressable
Market CAGR9.1%2027–2033
Target share16.5%from 9.1% today
Revenue ambition$1.50Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 16.5% | At risk |
| Revenue | $794M | $1.50B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 28.7% | 41.3% | Behind |
| Customer retention | 91.0% | 96.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Source Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation Type capability
A defensible second engine — invest in Formulation Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Source Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $213M capacity & capability investment
- Greenlight bolt-on M&A in Formulation Type
- Authorise North America expansion plan
- Fund R&D program for Source Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Omega-3 Ingredient for Pharmaceutical Market conversation — a $3.19B market you can size, segment and defend in minutes.
Market size · 2033$3.19Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers1,220+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Source Type
Goal Grow share in Source Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 2 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
DSM Nutritional ProductsCroda International PlcBASF SEMartek Biosciences Corporation (a subsidiary of DSM)Omega Protein CorporationGC Rieber Oils ASEPAX ASLysoveta+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Omega-3 Ingredient for Pharmaceutical Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Omega-3 Ingredient for Pharmaceutical Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Omega-3 Fish Oil Supplements Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportOmega-3 Ethyl Ester Capsule Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportOmalizumab Monoclonal Antibody Biosimilars Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOmalizumab for Injection Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportOmalizumab Biosimilars Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportOmadacycline Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportOlverembatinib Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportOlsalazine Sodium Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportOlopatadine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportOlmesartan Medoxomil API Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportOlmesartan API Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportOlive Leaf Supplements Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.